A new nanoparticle system to overcome drug resistance in prostate cancer treatment
miR-205 Nanoparticle system circumvents docetaxel resistance in prostate cancer
This study is testing a new way to deliver tiny particles that carry helpful molecules directly to prostate cancer cells, hoping to make chemotherapy work better and with fewer side effects for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Rio Grande Valley NIH-funded |
| Lab location | 1 site (Edinburg, United States) |
| Project ID | NIH-10810833 on NIH RePORTER |
What this research studies
This research focuses on developing a nanoparticle system that delivers microRNA to prostate cancer cells, aiming to overcome resistance to the chemotherapy drug docetaxel. By using a dual-layer magnetic nanoparticle formulation, the study seeks to enhance the delivery of therapeutic miRNAs directly to tumor sites, improving treatment effectiveness while minimizing side effects. The approach addresses the challenges of current miRNA delivery methods, which often involve risks and low therapeutic outcomes. Patients may benefit from a more effective treatment option that targets their cancer more precisely.
Who could benefit from this research
Good fit: Ideal candidates for this research are prostate cancer patients who have shown resistance to docetaxel treatment.
Not a fit: Patients with early-stage prostate cancer who have not yet undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment for prostate cancer patients who are resistant to standard chemotherapy.
How similar studies have performed: Other research has shown promise in using nanoparticle systems for drug delivery in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Edinburg, United States
- University of Texas Rio Grande Valley — Edinburg, United States (Active)
Researchers
- Principal investigator: Yallapu, Murali Mohan — University of Texas Rio Grande Valley
- Study coordinator: Yallapu, Murali Mohan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.